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diagnostic markers, such as the level and function of C1-INH, 
C1q and C4 to reliably diagnose the angioedema type, and 
considered the use of genetic testing to identify mutations 
in  FXII or  XPNPEP2  that have been associated with HAE-nC1-
INH and ACEI-AAE, respectively. Due to the lack of approved 
treatments for HAE-nC1-INH, ACEI-AAE and C1-INH-AAE, the 
group presented several case studies in which therapies ap-
proved for treatment of HAE types I/II, such as icatibant, ecal-
lantide and pasteurized, nanofiltered C1-INH, were success-
ful. It was uniformly agreed that further studies are needed 
to improve the diagnosis and treatment of angioedema oth-
er than HAE types I/II.  © 2014 S. Karger AG, Basel 
 Introduction 
 Hereditary angioedema (HAE) types I/II (HAE with 
deficient C1-inhibitor, C1-INH, and HAE with dysfunc-
tional C1-INH) are well-characterized forms of HAE, 
which can be diagnosed by low functional levels of C1-
INH and, in most cases, have a positive family history. 
Several treatments exist for HAE types I/II, including C1-
INH, the β2 bradykinin receptor antagonist icatibant, and 
the kallikrein inhibitor ecallantide, which have been suc-
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 Abstract 
 Several types of angioedema exist beyond hereditary angio-
edema (HAE) types I/II; however, the diagnostic and treat-
ment needs of these conditions are not well understood. No-
ticeably, there are no licensed treatments available for other 
forms of angioedema beyond HAE types I/II, and similarly 
they are unresponsive to conventional antihistamine/gluco-
corticoid treatment. A group of angioedema experts met in 
Budapest in May 2013 to discuss such issues, presenting 
their experience, reviewing available literature and identify-
ing unmet diagnostic and treatment needs in three different 
angioedema types: HAE with normal C1-inhibitor (C1-INH; 
previously referred to as type III HAE); nonallergic angioten-
sin-converting enzyme inhibitor (ACEI)-induced angioede-
ma (ACEI-AAE), and acquired angioedema due to C1-INH de-
ficiency (C1-INH-AAE). The group identified unmet diagnos-
tic and treatment needs in HAE-nC1-INH, C1-INH-AAE and 
ACEI-AAE, explored remedies and made recommendations 
on how to diagnose and treat these forms of angioedema. 
The group discussed the difficulties associated with using 
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cessful in the treatment of HAE types I/II for many years 
 [1] . However, for other forms of bradykinin-mediated 
angioedema, the diagnostic and treatment needs are less 
well understood. Bradykinin-mediated forms of angio-
edema include both hereditary, i.e. HAE types I and II, 
and nonheredity forms, i.e. acquired angioedema with 
C1-INH deficiency  [2] . During bradykinin-mediated an-
gioedema, increased levels of bradykinin results in over-
activation of β2 bradykinin receptors and subsequently 
increased tissue permeability, vasodilation and edema 
( fig.  1 ). Bradykinin-mediated forms of angioedema are 
distinct from allergic reactions, as they do not respond to 
conventional therapies such as antihistamines or cortico-
steroids. 
 To address these points, a group of international an-
gioedema experts gathered in Budapest in May 2013 to 
present their experience, review available literature and 
explore the feasibility of using medications approved for 
HAE types I and II in the treatment of other forms of an-
gioedema. The HAE expert group explored three other 
forms of bradykinin-mediated angioedema: HAE with 
normal C1-INH (HAE-nC1-INH), formerly referred to 
as type III HAE, which can result from FXII mutations 
(FXII-HAE) or an unknown cause (U-HAE), nonallergic 
angiotensin-converting enzyme inhibitor (ACEI)-in-
duced angioedema (ACEI-AAE), and acquired angioede-
ma due to C1-INH deficiency (C1-INH-AAE)  [3] . For 
these forms of angioedema there are currently no licensed 
treatments available, and no improvements are observed 
with conventional antihistamine/glucocorticoid treat-
ment. Furthermore, in these forms of angioedema, C1-
INH antigenic levels and function may be normal and 
there may be no family history which can make diagnosis 
of these forms difficult.
 Here we report on the findings of the HAE expert 
meeting and summarize the thoughts and opinions of 
HAE experts on the key characteristics ( table 1 ) and chal-
lenges associated with diagnosing these forms of angio-
edema. We present evidence from the HAE expert meet-
ing that suggest that treatments, such as C1-INH, which 
are used in the treatment of HAE I/II may be beneficial in 
the treatment of FXII-HAE/U-HAE, ACEI-AAE and C1-
INH-AAE.
 Challenges Associated with Diagnosing Alternative 
Forms of Angioedema 
 During the angioedema expert meeting, participants 
stressed the importance of ensuring that the exact medi-
cal condition is treated. Allergic forms of angioedema are 
histamine dependent and can often be determined by the 
presence of urticaria and successful treatment with anti-
histamines/glucocorticoids. Since the majority of cases 
are histamine dependent, it was uniformly agreed that 
initial cases of angioedema should be treated as such and 
given short-term treatment with antihistamines/gluco-
corticoids. An alternate diagnosis should be established 
pnfC1-lNH
or
recombinant
human c1-INH
C1-lNH
Prekallikrein
Kallikrein
HMW kininogen
? Bradykinin
Bradykinin ??????????? Icatibant
Degradation
Ecallantide
ACEl
ACE
Vasodilation/increased
permeability/edema
FXll
FXlla
 Fig. 1. Mechanism of bradykinin-mediated 
angioedema. Increased bradykinin levels 
lead to vasodilation, increased tissue perme-
ability and edema. Degradation of bradyki-
nin is mediated by kininases. ACE, which 
plays a role in degradation of bradykinin, 
can be inhibited by ACEIs. Production of 
bradykinin can be inhibited by ecallantide, 
which acts on kallikrein, or by C1-INH, 
which acts to inhibit formation of kallikrein 
and HMW kininogen. Activation of the 
bradykinin β2 receptor is inhibited by icati-
bant. In angioedema cases where C1-INH is 
deficient, treatment with pnfC1-INH or re-
combinant human C1-INH replaces endog-
enous C1-INH to control bradykinin levels. 
Dashed lines indicate inhibition. ACE = 
Angiotensin converting enzyme; ACEI = 
angiotensin converting enzyme inhibitor; 
HMW = high molecular weight; C1-INH = 
C1-inhibitor; pnfC1-INH = pasteurized, 
nanofiltered C1-INH.
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in cases that are nonresponsive to short-term treatment 
with antihistamines/glucocorticoids. Diagnostic tests in-
vestigating C1-INH, C1q or C4 levels could be used as a 
diagnostic tool; however, these may not always indicate if 
attacks are histamine or bradykinin induced ( table 1 ).
 HAE with Normal C1-INH  
 In FXII-HAE/U-HAE, antigenic and functional levels 
of C1-INH, C1q and C4 are normal, so diagnostic testing 
using these markers cannot be used. FXII-HAE/U-HAE 
can be characterized by recurrent angioedema attacks 
 Table 1.  Characteristics of hereditary, nonallergic drug-induced and acquired forms of angioedema
Type of 
angioedema
Description  Diagnostic markers Genetic 
factor
Diagnosis
C1 -INH
antigenic 
level
C1-INH 
functional 
level
C4 C1q Anti-
C1-INH
antibodies
HAE I/II Symptoms present in childhood and
worsen around puberty.
Attacks target extremities,
genitourinary tract, bowel, face, upper 
airway.
Abdominal/bowel and upper airway
attacks common.
Prodromal symptoms, e.g. erythema
marginatum.
Attacks last 72–96 h.
Frequency of attacks variable.
Symptoms worsened by stress/trauma,
estrogens, infections.
Low in HAE 
type I.
Normal or
elevated in
HAE type II
Low Low Normal No C1-INH 
gene
Family history of 
angioedema present 
in 75%.
Mutation in C1-INH 
gene.
Low functional
levels of C1-INH
and C4.
Normal C1q.
HAE-nC1-INH 
(FXII-HAE/
U-HAE)
Similar to types I/II but:
Older age of onset: 20–30 years. 
Fewer attacks/longer attack-free
intervals.
Higher percentage of cutaneous, 
facial and upper airway attacks.
Fewer abdominal attacks.
Multisite attacks rare.
Recurrent angioedema without 
wheals.
Duration of attacks >24 h.
Trigger factors: estrogens. 
Normal Normal Normal Normal No FXII gene 
(in some 
cases)
Family history of 
angioedema present 
in 58%.
FXII mutation
reported in 10–25%.
Normal antigenic 
and functional
levels of C1-INH, 
normal levels of C4 
and C1q.
Nonallergic 
ACEI-AAE
Most common cause: ACEI.
Incidence of ACEI-induced angioedema 
0.1–0.7%.
Attacks target face, tongue, lips, pharynx
and larynx.
Bowel and extremities less commonly
affected.
Risk factors: female sex, age, ethnic
origin, previous drug interactions,
allergies, smoking, obesity.
Normal Normal Normal Normal No XPNPEP2/
APP (in 
some cases)
Associated with 
ACE inhibitors.
Polymorphisms in 
XPNPEP2/APP
associated with
higher risk.
Normal antigenic 
and functional 
levels of C1-INH, 
normal levels of C4 
andC1q.
C1-INH-AAE Associated with lymphoproliferative
disorder, autoimmune disorders,
lymphoma or infection that lead to
depletion of C1-INH, or associated
autoantibodies against C1-INH lead 
to inactivation.
Older age of onset: >40 years.
Attacks target face, upper airway 
and abdomen.
Multisite attacks rare.
Low/
normal
Low Low Low 
(in 
most 
cases)
In some 
cases
None Presence of C1-INH 
autoantibodies in 
some patients.
Low or normal
antigenic level and 
low functional level 
of C1-INH, low
levels of C4 and
C1q.
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without wheals, a prolonged duration of attacks, an older 
age of symptom onset, with the mean age of first attack 
26.8 ± 14.9 years, and a higher percentage of facial attacks 
 [2, 4] . Furthermore, key differentiating factors for FXII-
HAE/U-HAE are that it can be triggered by estrogens  [4, 
5] and has been associated with mutations in the  FXII 
 gene  [6–8] .
 Exposure to estrogens, either during pregnancy or 
from oral contraceptives, has been shown to exacerbate 
the severity of attacks in many FXII-HAE/U-HAE pa-
tients  [4, 9] . Furthermore, a subset of FXII-HAE/U-HAE 
patients has been shown to be estrogen-dependent, i.e. 
swelling only occurs at the time of estrogen exposure. 
Angioedema expert discussion of unpublished experi-
ence identified that 80% of French cases worsened with 
estrogen, 13% of cases were estrogen dependent (only 
occurring with contraceptive use or pregnancy), and 
only 7% of cases were not influenced by estrogen (as pre-
sented at the 8th C1-INH deficiency workshop  [10] ). 
However, this is in contrast to the experience of other 
experts at the meeting; in a Spanish cohort the majority 
of patients (85%) were estrogen dependent, and 15% 
were estrogen related (as presented at the 8th C1-INH 
deficiency workshop  [10] ). Furthermore, published data 
from Vitrat-Hincky et al.  [5] observed that the condition 
of 54.5% of women worsened with estrogen, and 23% 
were estrogen dependent  [11] . These data highlight that 
the influence of estrogen on FXII-HAE/U-HAE is highly 
variable. 
 Several mechanisms have been proposed for the estro-
gen dependence observed in FXII-HAE/U-HAE that in-
volve the effects of estrogen on both bradykinin produc-
tion and degradation. High levels of estrogen that occur 
during pregnancy or from oral contraceptive use have 
been shown to increase the level of FXII due to an estro-
gen response element in the gene promoter. As illustrated 
in  figure 1 , FXII, when activated, converts prekallikrein 
to kallikrein; the first step in bradykinin production and 
increased FXII could result in increased bradykinin pro-
duction. Additionally, under high-estrogen conditions, 
levels of C1-INH have been shown to decrease, which 
would reduce inhibition of FXII and kallikrein and fur-
ther promote increased bradykinin production ( fig.  1 ). 
High levels of estrogen may also reduce the degradation 
of bradykinin through inhibition of angiotensin-convert-
ing enzyme (ACE) expression and possibly through a re-
duction of aminopeptidase P (APP) levels  [12] .
 Although FXII-HAE/U-HAE has been associated 
with mutations in the  FXII gene; mutations are only 
found in a small subset of patients  [4] and symptoms in 
patients with or without FXII mutations are similar  [11, 
13] . During the meeting it was reported that only 10–
25% of diagnosed French patients have a FXII  mutation. 
Furthermore, 42% of patients had no family history and 
disease symptoms can be highly variable. To illustrate 
this, a case report was presented of a female FXII muta-
tion carrier who experienced recurrent abdominal at-
tacks throughout puberty and pregnancy, together with 
some additional peripheral attacks. In contrast, her sis-
ter, also an FXII mutation carrier, only suffered attacks 
during pregnancy, and her mutation-carrying daughters 
are asymptomatic. The low percentage of FXII mutation 
carriers led to the question of how patients can be reliably 
identified by genotyping alone, and may explain the vari-
ability in incidence across other countries, for example 
American angioedema experts highlighted that patients 
with normal C1-INH levels and no family history of an-
gioedema would not be genotyped, thus few cases of 
FXII-HAE/U-HAE are reported there. Diagnosis of 
FXII-HAE/U-HAE therefore depends upon the inter-
play between genetic, clinical and laboratory factors, and 
key criteria to monitor include recurrence of angioede-
ma attacks, near normal C1-INH, C1q and C4, evidence 
of estrogen dependence and evidence of FXII mutations 
or family history.
 ACEI-Induced Angioedema 
 In ACEI-AAE, levels of C1-INH, C4 and C1q are nor-
mal and attacks commonly affect the head and neck, 
and can involve the mouth, tongue and larynx, which can 
lead to fatal laryngeal obstruction. ACE is an important 
regulator of bradykinin levels involved in the cleavage 
and degradation of bradykinin ( fig. 1 ). In the presence of 
ACEIs, degradation of bradykinin is dependent upon 
APP, neutral endopeptidase (NEP) and dipetidyl pepti-
dase IV (DPP-IV), and the blood and tissue levels of 
these enzymes are important factors in the prevention of 
ACEI-AAE  [14] . The reported incidence of ACE-AAE is 
0.1–2%  [14] ; however, some populations, such as African 
Americans, women and smokers, have a higher risk of 
developing ACEI-AAE  [2] .
 Polymorphisms in  XPNPEP2  [15, 16] and haplotype 
mutations in the  APP gene  [15, 17] have been identified 
as possible risk factors of ACEI-AAE; however, there is 
no clear genetic basis for the disease.  XPNPEP2  encodes 
APP, which is involved in the cleavage and inactivation 
of bradykinin. Polymorphisms in  XPNPEP2 have been 
linked with an increased risk, especially in black (African) 
women  [15, 18] . The increased incidence reported among 
African Americans and women may be due to reduced 
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plasma activity and levels of APP  [15] . On reviewing data 
from the University of Cincinnati on ACEI-induced an-
gioedema, 75% of patients presenting to the emergency 
department were African American. Due to the complex 
genetic background the question remains as to whether 
genotyping would be beneficial in identifying high-risk 
patients.
 The risk of ACEI-AAE is also increased in patients 
receiving treatment with DPP-IV inhibitors that are 
used to treat diabetes, or NEP inhibitors used to treat 
hypertension  [14] . A clinical study of patients receiving 
omapatrilat, an NEP inhibitor currently under develop-
ment, found that it was more frequently associated with 
angioedema than the ACE inhibitor enalapril (2.17 vs. 
0.68%)  [19] . A premarketing study of the DPP-IV in-
hibitor vildagliptin found that whilst there was no as-
sociation between vildagliptin treatment alone and an-
gioedema, use of vildagliptin alongside ACEI resulted 
in a small increased risk of angioedema, as shown by 14 
confirmed angioedema cases amongst 2,754 vilda-
gliptin patients compared to 1 amongst 1,819 in a com-
parator product (odds ratio 4.57; 95% CI 1.57–13.28) 
 [20] .
 ACEI-AAE often occurs early in the course of ACEI 
treatment, with around 50% of cases occurring in the first 
week of treatment  [14, 21] ; however, it can occur several 
months or years after initial treatment  [2] . While most 
attacks resolve within 24–48 h of discontinuation of 
ACEI, they can recur weeks or months after treatment 
discontinuation  [15] . The variable time between the start 
of ACEI treatment and attack is another factor that can 
complicate the diagnosis of ACEI-AAE.
 Acquired Angioedema due to C1-INH Deficiency  
 C1-INH-AAE is associated with lymphoproliferative 
disorders such as monoclonal gammopathy of uncertain 
significance, malignant lymphoma, neoplasm, infections 
and autoimmune disorders. C1-INH-AAE can be charac-
terized by large-scale activation of complement pathways 
and a breakdown of C1-INH  [22, 23] . A reduction in C1-
INH may be via an interaction with lymphatic tissues 
which have been shown to consume C1-INH  [24] . In 
some cases C1-INH-AAE may result from autoantibodies 
against C1-INH  [22] . Anti-C1-INH antibodies bind to 
C1-INH and prevent the formation of C1-INH protein 
complexes. The presence of autoantibodies can also con-
vert C1-INH into a substrate for proteases which results 
in cleavage of C1-INH  [22, 24] . This leads to depletion of 
components of the complement system, resulting in low 
antigenic levels and low functional levels of C1-INH, low 
levels of C4 and, in most cases, low C1q  [2] . As C1-INH-
AAE is associated with low C1-INH, its clinical presenta-
tion is similar to HAE types I/II. However, unlike HAE 
forms, C1-INH-AAE is not associated with an inherited 
condition so has no family history  [2] and is associated 
with a later age of symptom onset, typically in the 4th or 
5th decade of life  [2] . In 4 cases presented at the angio-
edema expert meeting, no patients had a family history of 
angioedema, 2 patients had autoantibodies against C1-
INH and all patients had underlying lymphoproliferative 
disease (3 with non-Hodgkin’s lymphoma, 1 with multi-
ple myeloma).
 Diagnosis is usually made by laboratory testing that 
identifies low C4, C1-INH and low C1-INH function. 
C1q is low in most cases and helps distinguish C1-INH-
AAE from HAE types I/II; nevertheless, not all cases have 
low C1q, making differential diagnoses difficult. In these 
cases, genetic analysis to differentiate the hereditary from 
the acquired form may assist with diagnosis  [22] . The 
presence of autoantibodies against C1-INH may be an 
indicator of C1-INH-AAE  [2] , although they are only ob-
served in 70% of patients  [25] and thus are not always 
present, as demonstrated by the cases discussed by the 
expert group.
 Unmet Treatment Needs: The Current Therapeutic 
Landscape 
 Currently, there are no approved therapies for FXII-
HAE/U-HAE, ACEI-AAE or C1-INH-AAE. Participant 
experience and unpublished case studies discussed dur-
ing the meeting showed that therapies approved for use 
in HAE types I/II, including pasteurized, nanofiltered 
C1-INH (pnfC1-INH, Berinert; CSL Behring, Marburg, 
Germany), ecallantide (Kalbitor; Dyax, Burlington, 
Mass., USA) and icatibant (Firazyr; Shire Orphan Thera-
pies GmbH, Berlin, Germany), have successfully resolved 
attacks of different types of bradykinin-induced angio-
edema. Icatibant, ecallantide and C1-INH have been 
shown to be effective treatments for ACEI-AAE  [15, 26] , 
C1-INH-AAE  [2, 27] and FXII-HAE/U-HAE  [9] ( ta-
ble 2 ), and are currently the focus of ongoing clinical tri-
als in the USA  [28, 29] . Fresh frozen plasma (FFP) has 
been successfully used in the treatment of FXII-HAE/ U-
HAE  [2, 30] and ACEI-AAE  [2, 15] , and has been recom-
mended as a treatment for angioedema when no specific 
treatment options are available  [2] . However, the use of 
FFP was discussed during the HAE expert meeting as, al-
though FFP is a successful treatment option for angio-
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edema due to the presence of angiotensin II in plasma 
that acts to degrade bradykinin  [15] , it should be used 
with caution for acute treatment of angioedema attacks 
due to the presence of substrate, which may exacerbate 
swelling  [2, 15] . In countries where other options are 
available, FFP is not recommended due to the presence of 
substrate and because it carries a small risk of viral trans-
mission  [2, 3] , as with other plasma-derived products. 
 During the HAE expert meeting several case studies 
on the use of C1-INH in alternative angioedema types 
were presented. For FXII-HAE/U-HAE, there are limit-
ed data available on the therapeutic efficacy of treatments 
 [26] ; however, C1-INH has been shown to be moderate-
ly or very effective in most patients when used to treat 
laryngeal attacks  [11] , for short-term prophylaxis  [11] or 
when used to treat acute attacks in patients with FXII 
mutations  [6] . In the case study reported at the angio-
edema expert meeting, a patient with the FXII mutation 
was successfully treated with pnfC1-INH for edematous 
attacks during pregnancy and for short-term prophylax-
is during delivery. French patients who suffered frequent 
attacks ( ≥ 7.2/year) were treated with pnfC1-INH (7%) 
and a small number of patients received pnfC1-INH 
 prophylactically. The national French registry, COBRA 
(the French National Center for Bradykinin-Mediated 
Angioedema), includes patients with FXII-HAE/U-HAE 
who have been treated with pnfC1-INH. So far, 16 at-
tacks have been successfully treated, with 75% of pa-
tients showing improvements within the first hour after 
administration.
 Several case reports of ACEI-AAE were presented at 
the angioedema expert meeting. The effectiveness of 
pnfC1-INH was illustrated in a case study  [31] and in a 
small open-label study where lingual and buccal attacks 
resolved. A randomized, double-blind, multicenter phase 
III trial of pnfC1-INH in ACEI-AAE is currently under-
way in Germany to assess the time to complete resolution 
of signs and symptoms of acute ACE-induced angioede-
ma of the upper airway tract compared to placebo when 
given on top of standard treatment  [32] .
 For C1-INH-AAE, all 4 unpublished cases discussed at 
the meeting were successfully treated with pnfC1-INH 
and 2 patients were prophylactically treated with pnfC1-
INH prior to dental procedures. Additionally, it was not-
ed that some patients, particularly those with autoanti-
bodies, required higher doses of pnfC1-INH. This could 
be due to patients with autoantibodies becoming resistant 
to C1-INH treatment  [2, 22, 24] ; in these patients, C1-
INH-AAE can be successfully treated with icatibant or 
ecallantide  [27] . C1-INH-AAE is linked to lymphoprolif-
erative diseases, and it has been observed that cytotoxic 
treatment of the lymphoproliferative diseases associated 
with C1-INH-AAE variably reverses the complement im-
pairment, leading to improvement of the angioedema 
symptoms  [24] .
 The question of why C1-INH treatment would be ef-
fective in forms of angioedema in which C1-INH levels 
are normal was raised by some angioedema experts. Dur-
ing the discussion participants proposed that, mechanis-
tically, treatment with C1-INH concentrate might pre-
vent further production of bradykinin, although it was 
suggested that there may be a latency in response due to 
the time taken to metabolize preexisting bradykinin 
( fig. 1 ).
 Discussion 
 The angioedema expert group identified unmet diag-
nostic and treatment needs in FXII-HAE/U-HAE, ACEI-
AAE and C1-INH-AAE. In particular, they noted that di-
agnostic markers such as levels of C1-INH, C4 or C1q 
cannot be reliably used to differentiate between angio-
edema types. For FXII-HAE/U-HAE and ACEI-AAE the 
levels of C1-INH, C4 and C1q are normal but comple-
mentary testing may be useful to provide a differential 
diagnosis from HAE types I/II. The presentation of C1-
INH-AAE is similar to HAE type I/II, so differentiating 
these types can be difficult using diagnostic markers; low 
C1-INH and C4 levels are expected, but C1q may be nor-
mal. If the C1q level is normal ( ∼ 30% of cases)  [33] , ge-
netic testing can distinguish between C1-INH-AAE and 
HAE types I/II; however, mutation of the C1-INH gene 
cannot be detected in 8–10% of cases of HAE types I/II 
 [34] . The presence of autoantibodies in C1-INH-AAE 
may be a useful diagnostic marker, although these are not 
present in all cases.
 The expert consensus was that more definitive test-
ing is essential for angioedema, not only to determine 
bradykinin- from histamine-induced angioedema, but 
also to distinguish different types of bradykinin-in-
duced angioedema. Definitive treatment for FXII-HAE/
U-HAE and other angioedema types will require tests 
that can confirm the diagnosis. Whilst there are cur-
rently no approved therapies for FXII-HAE/U-HAE, 
ACEI-AAE and C1-INH-AAE, evidence presented dur-
ing the HAE expert meeting indicated that therapies 
such as C1-INH, icatibant and ecallantide can be effec-
tive. Further data from clinical studies are needed to 
confirm the efficacy of the medications discussed above 
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in bradykinin-induced diseases other than HAE types I/
II; however, several promising trials in ACEI-AAE are 
currently ongoing.
 Key Clinical Points 
 The following key clinical points were agreed upon at the 
 meeting:
 • ACEIs are the leading cause of drug-induced angioedema. 
 • C1-INH-AAE is not associated with a hereditary C1-INH defi-
ciency, is often associated with a C1-INH autoantibody and a 
low C1, and occurs most commonly in patients aged >40 years. 
 • FXII-HAE/U-HAE has a positive family history, symptom on-
set is most often at age 20–30 years, it is largely associated with 
estrogens and is observed in patients with or without mutation 
in the  FXII gene. 
 Acknowledgements 
 The authors would like to thank all participants of the interna-
tional angioedema expert meeting for the stimulating discussion 
and exchange of knowledge that took place during the meeting. 
The international angioedema expert meeting and the preparation 
of this article were supported by CSL Behring. Editorial assistance 
was provided by Meridian HealthComms, Plumley, UK. 
 References 
 1 Bork K, Steffensen I, Machnig T: Treatment 
with C1-esterase inhibitor concentrate in type 
I or II hereditary angioedema: a systematic lit-
erature review. Allergy Asthma Proc 2013; 34: 
 312–327. 
 2 Lang DM, Aberer W, Bernstein JA, Chng HH, 
Grumach AS, Hide M, Maurer M, Weber R, 
Zuraw B: International consensus on heredi-
tary and acquired angioedema. Ann Allergy 
Asthma Immunol 2012; 109: 395–402. 
 3 Cicardi M, Aberer W, Banerji A, Bas M, Ber-
nstein JA, Bork K, Caballero T, Farkas H, 
Grumach A, Kaplan AP, Riedl MA, Triggiani 
M, Zanichelli A, Zuraw B: Classification, di-
agnosis, and approach to treatment for angio-
edema: consensus report from the Hereditary 
Angioedema International Working Group. 
Allergy 2014; 69: 602–616. 
 4 Zuraw BL, Bork K, Binkley KE, Banerji A, 
Christiansen SC, Castaldo A, Kaplan A, Riedl 
M, Kirkpatrick C, Magerl M, Drouet C, Cicar-
di M: Hereditary angioedema with normal C1 
inhibitor function: consensus of an interna-
tional expert panel. Allergy Asthma Proc 
2012; 33(suppl 1):S145–S156. 
 5 Vitrat-Hincky V, Francois P, Labarere J, Re-
cule C, Stahl JP, Pavese P: Appropriateness of 
blood culture testing parameters in routine 
practice: results from a cross-sectional study. 
Eur J Clin Microbiol Infect Dis 2011; 30: 533–
539. 
 6 Bork K, Wulff K, Hardt J, Witzke G, Staubach 
P: Hereditary angioedema caused by missense 
mutations in the factor XII gene: clinical fea-
tures, trigger factors, and therapy. J Allergy 
Clin Immunol 2009; 124: 129–134. 
 7 Cichon S, Martin L, Hennies HC, Muller F, 
van Driessche K, Karpushova A, Stevens W, 
Colombo R, Renne T, Drouet C, Bork K, No-
then MM: Increased activity of coagulation 
factor XII (Hageman factor) causes hereditary 
angioedema type III. Am J Hum Genet 2006; 
 79: 1098–1104. 
 8 Dewald G, Bork K: Missense mutations in the 
coagulation factor XII (Hageman factor) gene 
in hereditary angioedema with normal C1 in-
hibitor. Biochem Biophys Res Commun 2006; 
 343: 1286–1289. 
 9 Bork K: Diagnosis and treatment of heredi-
tary angioedema with normal C1 inhibitor. 
Allergy Asthma Clin Immunol 2010; 6: 15. 
 10 Farkas H, Varga L: Abstracts of the 8th C1-
Inhibitor Deficiency Meeting, Budapest, 
Hungary. J Angioedema 2013; 1: 1–51. 
 11 Vitrat-Hincky V, Gompel A, Dumestre-Pe-
rard C, Boccon-Gibod I, Drouet C, Cesbron 
JY, Lunardi J, Massot C, Bouillet L: Type III 
hereditary angio-oedema: clinical and biolog-
ical features in a French cohort. Allergy 2010; 
 65: 1331–1336. 
 12 Binkley KE: Factor XII mutations, estrogen-
dependent inherited angioedema, and related 
conditions. Allergy Asthma Clin Immunol 
2010; 6: 16. 
 13 Bork K, Gul D, Hardt J, Dewald G: Hereditary 
angioedema with normal C1 inhibitor: clini-
cal symptoms and course. Am J Med 2007; 
 120: 987–992. 
 14 Kaplan A: Drug-induced angioedema. J An-
gioedema 2011; 1: 14–22. 
 15 Campo P, Fernandez TD, Canto G, Mayorga 
C: Angioedema induced by angiotensin-con-
verting enzyme inhibitors. Curr Opin Allergy 
Clin Immunol 2013; 13: 337–344. 
 16 Mahmoudpour SH, Leusink M, van der Put-
ten L, Terreehorst I, Asselbergs FW, de Boer 
A, Maitland-van der Zee AH: Pharmacoge-
netics of ACE inhibitor-induced angioedema 
and cough: a systematic review and meta-
analysis. Pharmacogenomics 2013;  14:  249–
260. 
 17 Cilia La Corte AL, Carter AM, Rice GI, Duan 
QL, Rouleau GA, Adam A, Grant PJ, Hooper 
NM: A functional XPNPEP2 promoter haplo-
type leads to reduced plasma aminopeptidase 
P and increased risk of ACE inhibitor-in-
duced angioedema. Hum Mutat 2011;  32: 
 1326–1331. 
 18 Woodard-Grice AV, Lucisano AC, Byrd JB, 
Stone ER, Simmons WH, Brown NJ: Sex-de-
pendent and race-dependent association of 
XPNPEP2 C-2399A polymorphism with an-
giotensin-converting enzyme inhibitor-asso-
ciated angioedema. Pharmacogenet Genom-
ics 2010; 20: 532–536. 
 19 Kostis JB, Packer M, Black HR, Schmieder R, 
Henry D, Levy E: Omapatrilat and enalapril in 
patients with hypertension: the Omapatrilat 
Cardiovascular Treatment versus Enalapril 
(OCTAVE) trial. Am J Hypertens 2004; 17: 
 103–111. 
 20 Brown NJ, Byiers S, Carr D, Maldonado M, 
Warner BA: Dipeptidyl peptidase-IV inhibi-
tor use associated with increased risk of ACE 
inhibitor-associated angioedema. Hyperten-
sion 2009; 54: 516–523. 
 21 Sabroe RA, Black AK: Angiotensin-convert-
ing enzyme (ACE) inhibitors and angio-oede-
ma. Br J Dermatol 1997; 136: 153–158. 
 22 Caballero T, Baeza ML, Cabanas R, Campos 
A, Cimbollek S, Gomez-Traseira C, Gonza-
lez-Quevedo T, Guilarte M, Jurado-Palomo 
GJ, Larco JI, Lopez-Serrano MC, Lopez-
Trascasa M, Marcos C, Munoz-Caro JM, Pe-
drosa M, Prior N, Rubio M, Sala-Cunill A: 
Consensus statement on the diagnosis, man-
agement, and treatment of angioedema medi-
ated by bradykinin. Part I. Classification, epi-
demiology, pathophysiology, genetics, clini-
cal symptoms, and diagnosis. J Investig 
Allergol Clin Immunol 2011; 21: 333–347. 
 23 Zingale LC, Castelli R, Zanichelli A, Cicardi 
M: Acquired deficiency of the inhibitor of the 
first complement component: presentation, 
diagnosis, course, and conventional manage-
ment. Immunol Allergy Clin North Am 2006; 
 26: 669–690. 
 24 Castelli R, Zanichelli A, Cicardi M, Cugno M: 
Acquired C1-inhibitor deficiency and lym-
phoproliferative disorders: a tight relation-
ship. Crit Rev Oncol Hematol 2013; 87: 323–
332. 
 25 Cicardi M, Zanichelli A: Angioedema due to 
C1 inhibitor deficiency in 2010. Intern Emerg 
Med 2010; 5: 481–486. 
D
ow
nl
oa
de
d 
by
: 
Se
m
m
el
we
is 
Un
iv 
of
 M
ed
ici
ne
   
   
   
   
   
   
   
   
   
 
19
8.
14
3.
55
.3
3 
- 7
/2
8/
20
15
 1
2:
35
:5
0 
PM
 Diagnosis and Treatment of Angioedema 
other than HAE 
Int Arch Allergy Immunol 2014;165:119–127
DOI: 10.1159/000368404
127
 26 Farkas H: Current pharmacotherapy of bra-
dykinin-mediated angioedema. Expert Opin 
Pharmacother 2013; 14: 571–586. 
 27 Zanichelli A, Bova M, Coerezza A, Petraroli 
A, Triggiani M, Cicardi M: Icatibant treat-
ment for acquired C1-inhibitor deficiency: a 
real-world observational study. Allergy 2012; 
 67: 1074–1077. 
 28 Clinical Trials: Evaluation of ecallantide for 
the acute treatment of angiotensin convert-
ing enzyme inhibitor induced angioedema. 
http:// clinicaltrials.gov/show/NCT01036659 
(accessed August 4, 2014). 
 29 Clinical Trials: Effect of bradykinin receptor 
antagonism on ACE inhibitor-associated 
 angioedema. http://clinicaltrials.gov/show/
NCT01574248 (accessed August 4, 2014). 
 30 Lumry WR: A report from ACAAI: highlights 
of presentations given at the 2012 Annual 
Meeting of the American College of Allergy, 
Asthma and Immunology (ACAAI). J Angio-
edema 2013; 1: 1–12 . 
 31 Nielsen EW, Gramstad S: Angioedema from 
angiotensin-converting enzyme (ACE) inhib-
itor treated with complement 1 (C1) inhibitor 
concentrate. Acta Anaesthesiol Scand 2006; 
 50: 120–122. 
 32 Clinical Trials: Randomized, double-blind, two 
arms, multicenter, phase III study of berinert 
for treatment of ACE induced angioedema. 
http://clinicaltrials.gov/show/NCT01843530 
(accessed August 4, 2014). 
 33 Cicardi M, Zanichelli A: Acquired angioede-
ma. Allergy Asthma Clin Immunol 2010; 6: 14. 
 34 Craig T, Aygoren-Pursun E, Bork K, Bowen 
T, Boysen H, Farkas H, Grumach A, Katelaris 
CH, Lockey R, Longhurst H, Lumry W, Mag-
erl M, Martinez-Saguer I, Ritchie B, Nast A, 
Pawankar R, Zuraw B, Maurer M: WAO 
guideline for the management of hereditary 
angioedema. World Allergy Organ J 2012; 5: 
 182–199. 
 35 Bouillet L, Boccon-Gibod I, Ponard D, Drou-
et C, Cesbron JY, Dumestre-Perard C, Mon-
nier N, Lunardi J, Massot C, Gompel A: Bra-
dykinin receptor 2 antagonist (icatibant) for 
hereditary angioedema type III attacks. Ann 
Allergy Asthma Immunol 2009; 103: 448. 
 36 Boccon-Gibod I, Bouillet L: Safety and effi-
cacy of icatibant self-administration for acute 
hereditary angioedema. Clin Exp Immunol 
2012; 168: 303–307. 
 37 Warrier MR, Copilevitz CA, Dykewicz MS, 
Slavin RG: Fresh frozen plasma in the treat-
ment of resistant angiotensin-converting en-
zyme inhibitor angioedema. Ann Allergy 
Asthma Immunol 2004; 92: 573–575. 
 38 Hassen GW, Kalantari H, Parraga M, Chirur-
gi R, Meletiche C, Chan C, Ciarlo J, Gazi F, 
Lobaito C, Tadayon S, Yemane S, Velez C: 
Fresh frozen plasma for progressive and re-
fractory angiotensin-converting enzyme in-
hibitor-induced angioedema. J Emerg Med 
2013; 44: 764–772. 
 39 Bas M, Greve J, Stelter K, Bier H, Stark T, 
Hoffmann TK, Kojda G: Therapeutic effi-
cacy of icatibant in angioedema induced by 
angiotensin-converting enzyme inhibitors: 
a case series. Ann Emerg Med 2010; 56: 278–
282. 
 40 Gallitelli M, Alzetta M: Icatibant: a novel ap-
proach to the treatment of angioedema relat-
ed to the use of angiotensin-converting en-
zyme inhibitors. Am J Emerg Med 2012; 30: 
 1664.e1–2. 
 41 Bas M, Greve J, Hoffmann TK, Reshef A, Ab-
erer W, Maurer M, Kivity S, Farkas H, Floc-
card B, Arcoleo F, Martin L, Sitkauskiene B, 
Bouillet L, Schmid-Grendelmeier P, Li H, Za-
nichelli A: Repeat treatment with icatibant for 
multiple hereditary angioedema attacks: 
FAST-2 open-label study. Allergy 2013; 68: 
 1452–1459. 
 42 Kaplan AP: Angioedema. World Allergy Or-
gan J 2008; 1: 103–113. 
D
ow
nl
oa
de
d 
by
: 
Se
m
m
el
we
is 
Un
iv 
of
 M
ed
ici
ne
   
   
   
   
   
   
   
   
   
 
19
8.
14
3.
55
.3
3 
- 7
/2
8/
20
15
 1
2:
35
:5
0 
PM
